Introduction
Regulation of HIV-1 gene transcription is mediated through the long terminal repeat (LTR) DNA sequence which is composed of several distinct regulatory motifs that serve as binding sites for ubiquitous and inducible transcription factors. The basal level of viral transcription which occurs at the immediate early stage after viral infection involves a core promoter consisting of a TATA element and a GC-rich motif, and binding sites for inducible transcription factors, the NF-kB and C/EBPb families of factors. 1 In addition to the influence of cellular factors, expression of the LTR at the early stage requires the participation of several viral encoded proteins including Tat which has the ability to cooperate with the promoter-binding proteins and several other factors involved in the modification of RNA polymerase II to stimulate the basal level of LTR transcription. 2 In recent years Hypericum perforatum, also known as St John's Wort, has received special attention due to its pharmacological properties, including antiseptic, spasmolytic, tonic, diuretic, and anesthetic remedies. 3, 4 Extracts from this plant are utilized in the treatment of mild to moderately severe depression. 5 Further, several studies have pointed to antitumor and antiviral activities of hypericin, a photosensitive and red colored naphthodianthrone which is suspected as the bioactive compound responsible for reversing depression symptoms. 6, 7 In this study, we identify a novel protein from a callus culture of St John's Wort that inhibits transcription of the HIV-1 LTR by interfering with the activity of C/EBPb and Tat.
Results and discussion
To assess the anti-HIV-1 activity of H. perforatum, we employed in vitro conditions to culture callus tissue of H. perforatum (Figure 1a ). Water-soluble protein extract from the callus showed the ability to suppress the basal transcription of the LTR in primary cultures of human microglia and astrocytes, as well as in U-937 cells ( Figure  1b ). Size fractionation of the callus extracts and protease treatment studies ruled out the effect of hypericin in the inhibition of LTR transcription, and suggested the involvement of protein(s) greater than 10 kDa in this event (data not shown). Polyacrylamide gel electrophoresis of the active fraction identified a major protein band of about 27 kDa in size ( Figure 1c, lane 2) . Results from Edman sequence analysis of three tryptic peptides from the highly purified 27 kDa protein allowed the design of DNA primers that were used to amplify an 800 bp cDNA fragment from RNA prepared from the callus culture with an open reading frame of 261 amino acids, designated p27 SJ . The predicted secondary structure of this novel protein is characterized by five a-helical domains scattered throughout the protein and a cluster of turns between the first and second helix near the N-terminus and central region of the protein. In addition, six clusters with b-sheet configurations were predicted (Figure 1d) . Results from cotransfection studies showed the ability of p27 SJ to decrease the basal transcription of the HIV-1 LTR in primary cultures of microglia, astrocytes, and U-937 cells (Figure 1e ). Conditional expression of p27 SJ in the human astrocytic cell line, U-87MG caused a marked decrease in transcriptional activity of the LTR upon the induction of p27 SJ production by treatment of cells with doxycycline (data not shown). To examine the impact of p27 SJ on the replication of HIV-1, primary cultures of human microglial cells were transfected with p27 SJ followed by infection with HIV-1 JR-FL . After 5 days, protein extracts were prepared and analyzed by Western blot using anti-p24 antibody for detection of HIV-1 protein, anti-p27 SJ antibody, and anti-Grb-2 antibody as a loading control. As seen in Figure 1f , from the intensity of the p24 band it is evident that expression of p27 SJ affects the level of HIV-1 gene expression and replication during the course of infection and has no effect on the housekeeping Grb-2 gene. We obtained similar results in HIV-1 infection of the erythroleukemic cell line, K562 (data not shown). Investigation of LTR deletion mutants identified the region between nucleotides À120 to À105 of the viral promoter, encompassing the binding site for the C/EBPb transcription factor located in juxtaposition of the NF-kB motif, as a primary target for p27 SJ for inhibiting viral transcription (Figure 2a) . Results from cotransfection studies revealed the ability of p27 SJ to suppress transcription of the LTR in cells where the viral promoter is stimulated by C/EBPb (Figure 2b ). Examination of p27 SJ by GST pull-down and co-immunoprecipitation/Western blot analyses established that this protein associates with C/EBPb (Figure 2c-e) . The DNAbinding activity of C/EBPb was evaluated in the absence SJ showed no significant effect on the binding of Sp1, a ubiquitous DNA-binding transcription factor, with its target DNA motif encompassing GC-rich nucleotides (data not shown).
The ability of various deletion mutants of p27 SJ in which 65 (p20), and 160 (p10) amino-acid residues were removed from the C-terminus of the protein to bind C/EBPb was tested by GST pull-down assay. As shown in Figure 3a , no detectable interaction between p10 and C/EBPb was observed (lane 5), whereas, p20 showed strong binding to C/EBPb (lane 4). Accordingly, unlike p20, p10 exhibited much less inhibitory effect on the DNA-binding activity of C/EBPb (Figure 3b , lane 4). These observations suggest that the interaction of p27 SJ with C/EBPb is mediated through the C-terminus of the protein.
Results from transcription studies showed that unlike p20, expression of p10 had less effect on transcription from the HIV-1 LTR (Figure 3c ). It has been shown that C/EBPb normally accumulates in the nucleus 8 ( Figure 3d ), while p27 SJ was found in the cytoplasm of the cells (Figure 3e, top) . Interestingly, in cells coexpressing p27 SJ and C/EBPb, C/EBPb was cytoplasmic and colocalized with p27 SJ (Figure 3e, top) . Under similar conditions, in cells expressing the p10 deletion mutant of p27 SJ , with no binding activity to C/EBPb, C/EBPb was localized in the nucleus (Figure 3e  bottom) . In p27 SJ -inducible cells, induction of p27 SJ expression caused perinuclear cytoplasmic accumulation Figure 3 Interaction of a specific domain of p27 SJ with C/EBPb alters C/EBPb activity. (a) GST pull-down assay using protein extract from cells expressing C/EBPb. GST fusion proteins containing full-length p27 SJ or mutants containing residues 1-197 (GST p20) or 1-100 (GST p10) were used. (b) Band-shift assay using total protein extract from cells transfected with CMV-p27 SJ or its variants, CMV-p20 or CMV-p10, along with CMV-C/EBPb. The position of a specific C/EBPb complex is shown by a bracket (top) and the nonspecific complex is indicated by the asterisk. (c) Luciferase assay depicting LTR transcription activity in U-87MG cells transfected with CMV-p27 SJ , CMV-p20, and CMV-p10. We have previously demonstrated the existence of a functional and physical interaction between C/EBPb and HIV-1 Tat proteins. 9 Expression of p27 SJ caused a substantial decrease in Tat-mediated activation of the LTR and had a negative effect on the cooperativity between C/EBPb and Tat in enhancing viral gene transcription (Figure 4a) . Evaluation of the effects of p27 SJ mutants, p20 and p10, on Tat-mediated activation of the HIV-1 promoter revealed the importance of the C-terminus of p27 SJ in the suppression of Tat activity (Figure 4b ). Of interest, p27 SJ also interacted with Tat through its C-terminal region (Figure 4c) . Furthermore, in cells expressing p27 SJ , Tat was found in the cytoplasm and colocalized with p27 SJ (Figure 4d ), suggesting that interaction of p27 SJ with Tat prevents its nuclear localization.
To test whether nuclear import of p27 SJ influences its inhibitory effect, p27
SJ was equipped with a nuclear localization signal (NLS), and its ability to suppress transcription of the LTR in the presence of Tat and C/EBPb was examined. Results from transfection assays revealed that unlike p27 SJ , p27 SJ -NLS failed to fully suppress the activity of Tat on the LTR promoter ( Figure  4e ). However, similar to p27 SJ , p27 SJ -NLS suppressed the basal transcription of the HIV-1 promoter (Figure 4f ). In cells expressing p27 SJ in the nucleus (p27 SJ -NLS), both Tat and C/EBPb appeared in the nucleus (Figure 4e and f) .
In the immediate early phase of infection, transcription of the HIV-1 genome relies almost entirely on host regulatory proteins, some of which are inducible and regulated by cytokines and immunomodulators. In this respect, several lines of evidence ascribe an important role for C/EBPb in the efficient transcription and replication of HIV-1 in several cell types, particularly in cells of myeloid lineage which support HIV-1 replication in brain and play an important role in the neuropathogenesis of AIDS. [10] [11] [12] [13] [14] [15] [16] Examination of several clinical samples from AIDS patients with dementia revealed a distinct mutation in the C/EBPb-binding site of the LTR SJ has a potential utility for blocking HIV-1-induced pathology in brain by suppressing HIV-1 replication and by inhibiting inflammation caused by proinflammatory Tat-inducible chemokines such as MCP-1.
Materials and methods

Callus culture
Callus culture from flowers of H. perforatum grown in the Institute of Botany (Armenia) were maintained in 250 ml flasks with 50 ml of nutrient MS 19 containing 30 g/l sucrose, 7 g/l Phytagar, auxins (2 mg/l a-naphthaleneacetic acid (NAA), 2 mg/l indole-3-acetic acid (IAA), 2 mg/l 2,4-dichlorophenoxyacetic acid (2,4-D)), cytokinins and purines (2 mg/l 6-benzylaminopurine (BAP) and 2 mg/l kinetin (6-furfurylaminopurine)). The cultures were kept at 261C with a light cycle of 16 h.
Plant extract preparation
Callus cultures (1-month old) of H. perforatum were collected and dried at 751C. In all, 100 mg of dried powder from callus were dissolved in 1 ml of lysis buffer, containing 30 mM Tris-HCl, pH 7.4, 167 mM NaCl, 0.1% Nonidet P-40 and protease inhibitor cocktail (Sigma, St Louis, MO, USA). Cell debris was removed by centrifugation at 14 000 r.p.m. for 5 min at 41C. Total soluble proteins from the callus were centrifuged at 10 000 r.p.m. for 5 min and the supernatant was recovered. Protease treatment was carried out by incubating extracts with 1 U/mg of Protease Factor Xa, an insoluble enzyme crosslinked to agarose beads (Sigma) for 15 min at 371C, and then cleaving by centrifugation at 14 000 r.p.m. for 1 min at 41C. For size fractionation of callus protein extracts, equal amounts of proteins were spun through a 10 kDa MilliPore Microcon YM-10 filter (Millipore, Ireland). For protein sequencing, 2.5 mg of protein were resolved by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) in transfer buffer containing 25 mM Tris (pH 7.4), 193 mM glycine, and 20% methanol. After transfer, the membrane was stained by Amido Black (Sigma) for 1 min, then destained, rinsed three times, and sent for protein sequencing by the Wistar Protein Microchemistry/MS Facility (Philadelphia, PA, USA).
Cell culture, transfection, and creation of cell lines
Primary human fetal microglia and astrocytes were prepared from 8-to 12-week-old human fetal brain tissue (purchased from Advanced Bioscience Resources Inc., Alameda, CA, USA) by a modified procedure based on the methods by Cole and de Vellis, 20 and Yong and Antel. 21 U-87MG, a cell line derived from human astrocytoma, 20 was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The human erythroleukemic cell line, K562, and human monocytic cells, U-937, were purchased from the ATCC. 
GFP-p27
SJ -NLS stable cell line
The U-87MG cell line constitutively expressing GFPp27 SJ -NLS was created by stably transfecting U-87MG cells with GFP-p27 SJ -NLS expression plasmid. Expression of the transgene was examined by Western blot analysis, using Living Colors full-length polyclonal antibody (BD Biosciences Clontech).
Cloning and preparation of cDNA library
Total RNA was extracted from callus tissue, using RNAqueous TM Total RNA Isolation Kit and Plant RNA Isolation Aid (Ambion, Austin, TX, USA) according to the manufacturer's directions. Approximately 1 mg of RNA was used for cDNA synthesis using reverse transcriptase (Roche Molecular Biochemicals, Indianapolis, IN, USA). The cDNA was amplified by 28 cycles of PCR with Taq DNA polymerase. The amplified DNA was gel purified and cloned into the TA cloning vector (Invitrogen, Carlsbad, CA, USA). Recombinant clones were identified by blue/white screening in the presence of isopropyl-1-thio-b-D-galactopyrasine (IPTG) and 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (XGal) and were screened for the presence of inserts by using restriction enzymes. Recombinant plasmid GSTp27 SJ was constructed by subcloning the EcoRI fragment from TA-p27 SJ into EcoRI-digested pGEX-2T plasmid. An ATG start codon and Kozak sequence were created in TA-p27 SJ , and p27 SJ was subcloned into pCDNA-6 Myc/ His-B (Invitrogen, Carlsbad, CA, USA), generating pCDNA6-B-p27 SJ (CMV-p27 SJ ) where p27 SJ gene (788 base pairs) was fused in frame with a C-terminal Myc/ His tag. The CMV-p27 SJ deletion mutants, CMV-p20 (1-196 amino acids) and CMV-p10 (1-100 amino acids) and the GST-p27 SJ deletion mutants (GST-p20 and GST-p10) were created by PCR amplification of EcoRI-XhoI fragments containing p27 SJ , cloned into EcoRI-XhoIdigested pCDNA-6-Myc/His A and pGEX-4T1. pTREp27 SJ was cloned by blunt end ligation of HindIII-PmeI fragment containing p27
SJ from pCDNA-6-B-Np27 SJ , with EcoRI-digested pTRE vector. The YFP-p27 SJ vector was generated by subcloning the EcoRI fragment from pCDNA-6-B-p27 SJ , containing p27 SJ , by blunt end ligation with XmaI-digested YFP vector. To generate the GFP-p27 SJ -NLS construct, a GFP-NLS expression vector equipped with a NLS was created first: 11Tat (NLS)
oligonucleotide primers were annealed, digested with BglII-HindIII and cloned into pLEGFP-C1 (BD Biosciences Clontech) upstream of the GFP gene. The resulting GFP-NLS expression vector was linearized using the MluI site upstream of GFP-NLS gene, and blunt ends ligated with the HindIII-BamHI fragment from YFP-p27 SJ . CMV-C/EBPb, CFP-C/EBPb and YFP-C/EBPb were created by PCR amplification of HindIIIBamHI C/EBPb cDNA from human genomic DNA and ligation with pCDNA6-Myc/His, pECFP-C1 and pEYFP-C1 (BD Biosciences Clontech) expression vectors. GST-C/EBPb was generated by blunt-end ligation of PCR-amplified HindIII-BamHI C/EBPb cDNA with SmaI-digested pGEX-2T. GST-Tat was cloned by PCR amplification of the BglII-EcoRI fragment containing HIV-1 Tat (1-86 amino acids), and ligation with Bam-HI-EcoRI-digested pGEX-2T. CFP-Tat was created by subcloning the BamHI-EcoRI fragment from CMV-Tat into BglII-EcoRI-digested pECFP-C1 expression vector. Expression plasmid CMV-HA-Tat has been previously described. 22 HIV-LTR deletion mutants (À476/+66) were generated by PCR amplification of specific regions of the LTR and cloned into HindIII-KpnI in pGL3-basic vector (Promega Corp., Madison, WI, USA). The sequence of all plasmids was verified by DNA sequencing using an ABI automatic sequencer.
Transfections
Transient transfection assays were carried out by the calcium phosphate technique as described, 23 using primary human fetal microglia or astrocytes and U-87MG cells. In brief, 2 Â 10 5 cells were plated on a 60 mm plate and grown overnight. Transfection was carried out with 1 mg of HIV-LTR-luciferase reporter constructs (full length and deletion mutants), in the presence and absence of 5 mg of GFP-p27 SJ -NLS, CMVp27 SJ and its deletion mutants, pCDNA-6-C/EBPb, or 1 mg of CMV-Tat, using various combinations. Experiments were designed to be promoter controlled with pCMV-X (pCDNA-6-B or pLEGFP-C1) plasmids added to equalize the total amount of promoter DNA in each transfection mixture. At 36 h post-transfection, cell extracts were prepared and equal amounts of proteins were assayed for luciferase activity. Each transfection was repeated a minimum of three times with different plasmid preparations.
EMSA and ChIP assays
C/EBPb band shift oligonucleotides were end-labeled with [g-32 P]ATP using T4 polynucleotide kinase (Roche Molecular Biochemicals, Indianapolis, IN, USA). Binding reactions with protein extracts from U-87 MG cells transfected with 10 mg of various DNA-expressing p27 SJ or its deletion mutants, and C/EBPb alone or in combinations, were carried out as described previously. 24 In super-shift experiments, 3 ml of anti-C/EBPb antibody (H-7; Santa Cruz) or control serum were preincubated with protein samples for 15 min at 41C prior to the addition of labeled DNA probe. Complexes were resolved by electrophoresis in 6% native polyacrylamide gels.
For ChIP assays, U-87MG cells were transfected with 1 mg of C/EBPb, pGL3-Luc LTR plasmid (À120/+66) and p27 SJ expression plasmid using the calcium phosphate method. After 48 h, cells were subjected to crosslinking with 1% formaldehyde and immunoprecipitated using anti-C/EBPb antibody followed by PCR amplification with primers flanking the region À120/+66 (Upstate Cell Signaling Solutions, Charlottesville, VA, USA).
Protein-protein interactions
For GST pull-down assay, [ 35 S]-labeled C/EBPb was synthesized using TNT-coupled transcription-translation wheat germ extract system (Promega, Madison, WI, USA) according to manufacturer's directions. GST protein, GST-p27 SJ and its deletion mutants, GST-Tat and GST-C/EBP-b recombinant proteins were produced in Escherichia coli and purified according to the method described previously. 25 Approximately 3 ml of 35 S-labeled in vitro translated protein (C/EBPb) were incubated with 5 mg of GST or GST fusion protein immobilized on glutathione sepharose beads in 300 ml of lysis buffer 150, plus 1 mg/ml bovine serum albumin for 1 h at 41C with continuous rocking. GST-pull-down assay was carried out as described previously. 26 Bound proteins were eluted with Laemmli sample buffer and analyzed by SDS-PAGE followed by autoradiography.
Preparation of cell extracts from the transfected cells for GST pull-down assay was performed according to the methods as previously described. 27 For immunoprecipitation/Western blot analysis, approximately 300 mg of extracts (from cells producing C/EBPb, CFP-Tat, p27 SJ or its deletion mutants) were incubated with 2 ml of anti-C/EBPb (H-7), anti-Myc antibody (Invitrogen), polyclonal anti-p27 SJ , antibody specific for CFP-Tat (Living Colors, BD Biosciences Clontech) overnight at 41C. In all, 30 ml of Protein A Sepharose were added, the samples were incubated at 41C for 1 h, and resins were pelleted, washed, and immunoprecipitated bound complexes were resolved by SDS-PAGE and analyzed by Western blot utilizing antip27 SJ antibody (rabbit polyclonal antibody obtained from Lampire Biological Laboratories Inc., Pipersville, PA, USA).
Immunocytochemistry assay
Fluorescence staining was performed as described previously. 28 Cells (1 Â 10 5 ) were transfected with 5 mg of various plasmids CMV-p27 SJ or YFP-p27 SJ , p10, GFPp27 SJ -NLS, CFP-Tat, CMV-C/EBPb and CFP-C/EBPb, alone or in combinations, or cells constitutively expressing GFP-p27 SJ -NLS and double stable cell line expressing p27 SJ were seeded in poly-L-lysine-coated glass slide chambers, and after 16 h incubation, cells were fixed and incubated with primary antibody (anti-C/EBPb, antiMyc antibody, or Living Colors polyclonal antibody), diluted in 1:250 in 0.1% PBS-BSA for 16 h at room temperature. Cells were washed in PBS, incubated with fluorescein-or rhodamine-conjugated secondary antibody diluted in 1:200 in 0.1% PBS/BSA for 1 h at room temperature in the dark, and washed again in PBS. For double staining, cells were further immunolabeled with primary antibody, and after brief washing and incubation with fluorescence-labeled secondary antibody, proteins were visualized via green or red fluorescence, and protein complexes were stained in yellow. Original magnification was Â 400. Fluorescence images were captured using IPLAB software. 
HIV-1 infection
Primary human microglial cells were maintained in microglial media. 20, 21 Cells in the log phase of growth were infected with JR-FL strain of HIV-1 as follows. In all, 50 ng of p24 containing virus stock were added to every 1 Â 10 6 cells. Cells were incubated with virus stock in a small volume of serum-free media for 2 h at 371C. The cells were then washed twice with PBS and fresh media containing 2% of FBS was added (500 000 cells/ml).
Western blot analysis was performed with protein extracts using anti-p24, anti-p27 SJ , and anti-Grb2 antibodies according to standard procedures.
